Live
- Biotech plays key role in combating chronic diseases: SVU VC
- Pariksha Pe Charcha: Participation mandatory for teachers, students
- SAAP chief opens 35th South Zone Aquatic championship
- Flamingo festival set to return in style
- A national loss: CM Naidu pays rich tribute to Manmohan Singh
- Formula E race: HC extends protection from arrest to KTR till Dec 31
- SCR extends special trains to handle festival rush
- SCR to run Maha Kumbh Mela-2025 special trains
- Kavitha braces for Maha Dharna in support of 42% BC quota in T
- Resolve woes of RRR alignment-hit people of Nalgonda: Dr Laxman
Cohance Lifesciences eyes global markets
Hyderabad: Cohance Lifesciences, a prominent player in India's pharmaceutical and specialty chemicals sector, is all set to hit the global market with...
Hyderabad: Cohance Lifesciences, a prominent player in India's pharmaceutical and specialty chemicals sector, is all set to hit the global market with its strategic expansion and commitment to innovation.
Backed by Advent, a global private equity player, Cohance has emerged as a frontrunner in Contract Development & Manufacturing Organization (CDMO) and Active Pharmaceutical Ingredient (API) space; with well-diversified customer and product mix. It has seven state-of-the-art facilities in India. Currently, CDMO contributes around 35 per cent of overall Cohance sales, growing at a CAGR of about 33 per cent during the last three years. “The company is now focused on the niche CDMO capabilities especially in the anti-body conjugate (ADC) payload space. This has earned us global recognition and a significant increase in the topline when it comes to CDMO,” said Dr Prasada Raju, Managing Director, Cohance Lifesciences
In the last four financial years, Cohance’s revenue grew at a CAGR of 16 per cent, while EBIDTA growth was at 27 per cent. For FY23, Cohance registered EBIDTA margin & PAT margin of 31 per cent and 21 per cent respectively.
